Latest / The Last Observer: Science and Beyond / Could We Actually Slow Down or Reverse the Aging Process?

Transcript

Could We Actually Slow Down or Reverse the Aging Process? · The Last Observer: Science and Beyond

• 0:00
  Speaker 1: For thousands of years, humanity has pretty much just accepted
• 0:04
  Speaker 1: aging as this immutable law of.
• 0:06
  Speaker 2: Nature, right, like it's just a given exactly.
• 0:09
  Speaker 1: We treat it like thermodynamics or you know, gravity. It's
• 0:12
  Speaker 1: just this slow, inevitable decay that's strictly governed by the passage.
• 0:16
  Speaker 2: Of time, a one way street.
• 0:18
  Speaker 1: Yeah. And it's funny because when we look at other
• 0:21
  Speaker 1: medical conditions, we expect a level of mechanical precision, like
• 0:25
  Speaker 1: if you fracture your femur, there's a jagged line on an.
• 0:28
  Speaker 2: X ray, very definitive, or inn a schemic.
• 0:31
  Speaker 1: Stroke, you could literally see the blockage in the brain's
• 0:34
  Speaker 1: blood vessels. But historically, when we look at the systemic
• 0:37
  Speaker 1: breakdown of the human body over decades, that precision just vanishes.
• 0:42
  Speaker 2: It becomes this vague concept.
• 0:44
  Speaker 1: Right. The medical establishment has long treated aging not as
• 0:47
  Speaker 1: a structural failure that we can fix, but is this mystical,
• 0:50
  Speaker 1: unavoidable fate. And the whole premise of our deep drive
• 0:54
  Speaker 1: today is that modern longevity science has basically thrown that
• 0:57
  Speaker 1: assumption out the windows completely.
• 0:59
  Speaker 2: It is a massive paradigm.
• 1:00
  Speaker 1: Shift because aging isn't being viewed as a mystical fate anymore.
• 1:04
  Speaker 1: It's being reframed as a biological disease, a mechanical failure
• 1:09
  Speaker 1: made of identifiable, treatable pathways.
• 1:12
  Speaker 2: Which changes everything for you, the listener, and for all
• 1:15
  Speaker 2: of us.
• 1:16
  Speaker 1: Right, so today we are going to unpack the biological
• 1:19
  Speaker 1: mechanics of why our tissues degrade. We'll look at the
• 1:23
  Speaker 1: radical interventions currently in human trials, and you know, examine
• 1:27
  Speaker 1: the massive structural hurdles standing between the lab and your
• 1:30
  Speaker 1: local pharmacy.
• 1:31
  Speaker 2: There are quite a few of those hurdles, unfortunately, Oh,
• 1:33
  Speaker 2: I'm sure.
• 1:35
  Speaker 1: But the big question we want to explore for you
• 1:36
  Speaker 1: today is whether modern medicine could actually end aging or
• 1:40
  Speaker 1: at least radically extend human health span within our lifetime.
• 1:44
  Speaker 2: And to understand that, we have to look at how
• 1:46
  Speaker 2: biogerontologists view disease today. Historically, things like heart disease, Alzheimer's, osteoarthritis,
• 1:52
  Speaker 2: they were seen as separate.
• 1:54
  Speaker 1: Issues, right, just bad things that happen to correlate with
• 1:56
  Speaker 1: getting old exactly.
• 1:58
  Speaker 2: But the modern consensus flips that entirely aging itself is
• 2:01
  Speaker 2: the upstream pathology.
• 2:03
  Speaker 1: Okay, so the aging is the root cause.
• 2:05
  Speaker 2: Yes, those localized diseases are just the downstream symptoms of
• 2:09
  Speaker 2: a central cellular decay.
• 2:11
  Speaker 1: That makes a lot of sense, actually it does.
• 2:13
  Speaker 2: And if we can isolate the molecular drivers of that decay,
• 2:17
  Speaker 2: we change human medicine from reactive symptom management to proactive
• 2:21
  Speaker 2: structural preservation.
• 2:23
  Speaker 1: Well, to stop the complex system from breaking down, you
• 2:25
  Speaker 1: first have to deeply understand exactly why it falls apart, right,
• 2:28
  Speaker 1: You need the blueprint exactly And the field has consolidated
• 2:32
  Speaker 1: this massive, complex failure of human aging into a framework
• 2:37
  Speaker 1: called the Hallmarks of aging, which is.
• 2:39
  Speaker 2: Such a helpful way to categorize it.
• 2:41
  Speaker 1: Originally there were nine, I think, but recent consensus has
• 2:45
  Speaker 1: expanded this to twelve core biological drivers.
• 2:48
  Speaker 2: Yeah, twelve core hallmarks, and we can divide them into
• 2:50
  Speaker 2: three distinct layers of cellular decline.
• 2:52
  Speaker 1: Three layers, Okay, break those down for me.
• 2:54
  Speaker 2: Sure, So those three layers represent a chronological cascade of
• 2:58
  Speaker 2: biological failure. The primary are the root causes, the initial damage,
• 3:02
  Speaker 2: right the accumulating damage to our cellular machinery. This includes
• 3:07
  Speaker 2: things like genomic instability, telemeretrition, epigenetic alterations, and a loss
• 3:14
  Speaker 2: of proteostasis.
• 3:15
  Speaker 1: Basically, the baseline wear and tear of just being alive
• 3:18
  Speaker 1: and intabolizing.
• 3:19
  Speaker 2: Exactly the thermodynamic cost of living. Then, the second layer
• 3:23
  Speaker 2: consists of antagonistic hallmarks.
• 3:26
  Speaker 1: Antagonistic meaning the body is fighting back.
• 3:28
  Speaker 2: Basically, yes, these are the body's compensatory responses to that
• 3:33
  Speaker 2: initial primary damage. So nutrient sensing pathways get deregulated, mitochondria
• 3:39
  Speaker 2: begin to dysfunction, and cells enter sinescence.
• 3:41
  Speaker 1: Okay. In the third layer, that would be the systemic
• 3:44
  Speaker 1: decline right.
• 3:44
  Speaker 2: Correct, the integrative hallmarks. This is where that localized cellular
• 3:48
  Speaker 2: damage snowballs into total tissue level failure.
• 3:51
  Speaker 1: Like organ's actually failing.
• 3:53
  Speaker 2: Yeah. Stem cells become exhausted so they can't regenerate tissue.
• 3:56
  Speaker 2: An altered intercellular communication leads to systemic inflammation throughout the body.
• 4:01
  Speaker 1: The critical insight here, though, seems to be the deep
• 4:04
  Speaker 1: interconnectivity of these twelve hallmarks. They aren't just operating in isolation.
• 4:08
  Speaker 2: Not at all. They are deeply, deeply interconnected. Genomic instability
• 4:14
  Speaker 2: directly accelerates cellular sinesence, which in turn drives that systemic
• 4:19
  Speaker 2: inflammation we just mentioned, which then exhausts the stem cell pools.
• 4:24
  Speaker 2: It's a domino effect.
• 4:25
  Speaker 1: I do want to push back on the therapeutic strategy here, though,
• 4:29
  Speaker 1: because the traditional medical approach is highly compartmentalized, very much so,
• 4:33
  Speaker 1: like it's almost like a game of whack a mole.
• 4:35
  Speaker 1: The patient gets high blood pressure, You prescribe an ACE inhibitor.
• 4:39
  Speaker 1: Their kidneys start failing, they go see an a phrologist.
• 4:42
  Speaker 1: Their brain starts showing amyloid plaques. You treat them for
• 4:45
  Speaker 1: cognitive decline. We treat these failing organs in silos.
• 4:49
  Speaker 2: Which is deeply inefficient.
• 4:51
  Speaker 1: But wait, if these twelve hallmarks are all totally intertwined
• 4:54
  Speaker 1: at the foundation, isn't targeting that massive web of causes
• 4:59
  Speaker 1: infinitely more complicated?
• 5:00
  Speaker 2: It sounds like it would be.
• 5:01
  Speaker 1: Yeah, I mean, practically speaking, isn't that harder than just
• 5:04
  Speaker 1: treating a single failing organ.
• 5:06
  Speaker 2: It appears overwhelming at first glance, but targeting the network
• 5:09
  Speaker 2: is actually the key to a cure. It's much more
• 5:12
  Speaker 2: biochemically efficient. Well, the compartmentalized whack a mole approach is
• 5:16
  Speaker 2: ultimately futile because it ignores the upstream driver.
• 5:20
  Speaker 1: Right, You're just treating the symptom exactly.
• 5:22
  Speaker 2: Giving someone an ACE inhibitor doesn't fix the cellular senescence
• 5:26
  Speaker 2: or the mitochondrial dysfunction that caused their blood vessels to
• 5:29
  Speaker 2: stiffen in the first place.
• 5:31
  Speaker 1: You're just lowering the pressure, not fixing the pipes.
• 5:33
  Speaker 2: Perfect analogy. Solving aging doesn't require a discrete cure for
• 5:37
  Speaker 2: a heart attack, a separate cure for kidney disease, and
• 5:41
  Speaker 2: another one for Alzheimer's.
• 5:42
  Speaker 1: So you fix the foundation and the whole house.
• 5:44
  Speaker 2: Stabilizes precisely by intervening at the primary or antagonistic hallmarks,
• 5:50
  Speaker 2: you intercept the pathology before it ever becomes organ failure.
• 5:54
  Speaker 1: Okay, let's move to the frontline of those actual interventions.
• 5:57
  Speaker 1: We're moving from mapping these hallmarks to active biological engineering.
• 6:01
  Speaker 2: This is where it gets really exciting.
• 6:03
  Speaker 1: Yeah, and I want to start with one of the
• 6:04
  Speaker 1: most destructive antagonistic hallmarks. What happens when our cells refuse
• 6:10
  Speaker 1: to die when they are supposed.
• 6:12
  Speaker 2: To ah cellular senescence.
• 6:14
  Speaker 1: Right, Because in a healthy system, a normal cell has
• 6:18
  Speaker 1: a defined life cycle. It's governed by the Hayflick limit.
• 6:21
  Speaker 2: Which means it can only divide a certain number of
• 6:23
  Speaker 2: times exactly.
• 6:25
  Speaker 1: It ergoes mitosis, and when it takes on too much
• 6:27
  Speaker 1: DNA damage or its telomeres get too short, it initiates apoptosis.
• 6:32
  Speaker 2: Programmed cell death. The cell essentially sacrifices itself for the
• 6:36
  Speaker 2: good of the organism.
• 6:38
  Speaker 1: And then macrophages come in clear the debris and fresh
• 6:42
  Speaker 1: stem cells divide to replace it.
• 6:44
  Speaker 2: That is the optimal, healthy physiological response. It protects you
• 6:48
  Speaker 2: by eliminating damaged cells that could otherwise become cancerous.
• 6:52
  Speaker 1: But as mammalian tissue ages, that whole immune clearance mechanism
• 6:56
  Speaker 1: starts to degrade.
• 6:57
  Speaker 2: It does, and that's when things go wrong. Sustain critical damage.
• 7:01
  Speaker 2: They initiate the DNA damage response, but instead of completing apoptosis,
• 7:05
  Speaker 2: they just stop. They arrest. They permanently halt the cell cycle,
• 7:08
  Speaker 2: they stop dividing. They aren't contributing to the tissue, but
• 7:11
  Speaker 2: they absolutely refuse to die.
• 7:13
  Speaker 1: And these are sinessence cells, zombie cells.
• 7:15
  Speaker 2: Zombie cells is a great way to put it.
• 7:17
  Speaker 1: And their presence isn't neutral, Like if they were just inert,
• 7:20
  Speaker 1: just dead weight sitting there, that would be one thing.
• 7:22
  Speaker 2: But they are actively harmful.
• 7:24
  Speaker 1: Very they become actively destructive through something called the Sinessence
• 7:27
  Speaker 1: associated secretary phenotype or STSP.
• 7:31
  Speaker 2: The SASP is a major driver of aging.
• 7:34
  Speaker 1: I always like to think of the sap as a
• 7:37
  Speaker 1: highly toxic disgruntled employee in an office.
• 7:40
  Speaker 2: Oh, I like that analogy, right.
• 7:42
  Speaker 1: Like this cell refuses to do its job, but it
• 7:45
  Speaker 1: also refuses to quit and leave the.
• 7:47
  Speaker 2: Building, just taking of space.
• 7:48
  Speaker 1: Worse than that, instead of sitting quietly at its desk,
• 7:51
  Speaker 1: it walks around the office all day, spending toxic rumors,
• 7:55
  Speaker 1: ruining morale and actively destroying the productivity of all the
• 7:58
  Speaker 1: healthy employees around.
• 7:59
  Speaker 2: It captures the localized destruction perfectly. At a molecular level,
• 8:04
  Speaker 2: that toxic gossip is a potent cocktail of pro inflammatory.
• 8:08
  Speaker 1: Molecules, inflammatory cytokines and stuff.
• 8:10
  Speaker 2: Exactly, cytokines, chemokines, matrix matella proteinases. A single senescent cell
• 8:14
  Speaker 2: can degrade the local tissue matrix and actually induce sinessens
• 8:18
  Speaker 2: in perfectly healthy adjacent cells.
• 8:20
  Speaker 1: Wait, really, it makes the healthy cells turn into zombies too.
• 8:23
  Speaker 2: Yes, it's a localized inflammatory storm. It drives tissue fibrosis,
• 8:28
  Speaker 2: vascular calcification, and systemic chronic inflammation.
• 8:32
  Speaker 1: The famous inflammaging. You've got it, So the therapeutic goal
• 8:35
  Speaker 1: is obvious. How do we force these disgruntled zombie cells
• 8:39
  Speaker 1: to finally undergo apoptosis without hurting the healthy tissue.
• 8:43
  Speaker 2: And that brings us to our scientific counter attack.
• 8:46
  Speaker 1: Sen lytics, Right, drugs specifically engineered to target senescent cells
• 8:51
  Speaker 1: and destroy them. But how exactly does that work? How
• 8:54
  Speaker 1: does the senalytic drug know the difference between a healthy
• 8:57
  Speaker 1: cell and a zombie cell right next to it?
• 9:00
  Speaker 2: Down to something kind of senescent cell anti apoptotic pathways or.
• 9:03
  Speaker 1: Stack saves, Okay, scap saves.
• 9:05
  Speaker 2: Because they are highly damaged. Sinescent cells are constantly receiving
• 9:09
  Speaker 2: internal signals telling them to die, to undergo apoptosis.
• 9:12
  Speaker 1: Their own biology is screaming at them to self destruct.
• 9:15
  Speaker 2: Exactly, So to survive they have to drastically upregulate these
• 9:19
  Speaker 2: specific pro survival networks to suppress those death signals.
• 9:23
  Speaker 1: They have to build biological armor just to stay alive exactly.
• 9:27
  Speaker 2: But healthy cells don't need to upregulate those pathways because
• 9:30
  Speaker 2: they aren't fighting off massive internal damage.
• 9:33
  Speaker 1: So seenalytics exploit that specific vulnerability. The drugs target those
• 9:39
  Speaker 1: exact survival pathways precisely.
• 9:41
  Speaker 2: You inhibit the survival pathway, the sinescent cell is overwhelmed
• 9:45
  Speaker 2: by its own death signals and it dies.
• 9:47
  Speaker 1: Wow, And the healthy cells are fine because they weren't
• 9:49
  Speaker 1: relying on that armor.
• 9:50
  Speaker 2: Anyway, exactly. A great example is the combination of deseatinib
• 9:55
  Speaker 2: and corsetin the.
• 9:56
  Speaker 1: D plus Q cocktail. Desentative is a leukemia drug.
• 9:59
  Speaker 2: Right it is. It's a tyrosine kinase inhibitor, and corstin
• 10:03
  Speaker 2: is a naturally occurring flavonoid.
• 10:05
  Speaker 1: You can find it in onions and apples, I think, right.
• 10:08
  Speaker 2: But when administered together in high targeted doses, they strip
• 10:11
  Speaker 2: away that biochemical armor. The sinescent cells undergo apoptosis and
• 10:16
  Speaker 2: the healthy ones are largely unaffected.
• 10:18
  Speaker 1: I mean. The animal data on this D plus Q cotail,
• 10:21
  Speaker 1: it's just incredible. When they give this to naturally aged mice,
• 10:25
  Speaker 1: they see profound systemic restoration.
• 10:27
  Speaker 2: It's remarkable to watch.
• 10:29
  Speaker 1: Cardiovascular function improves, they get stronger. Yeah, And the craziest part,
• 10:34
  Speaker 1: it's been shown to extend the remaining life span of
• 10:37
  Speaker 1: elderly mice by up to a staggering thirty six percent.
• 10:41
  Speaker 2: Thirty six percent is massive in mammalian models, but for
• 10:45
  Speaker 2: you listening, it's the restoration of health span that's really
• 10:48
  Speaker 2: driving the clinical translation to humans.
• 10:50
  Speaker 1: Because we aren't quite prescribing scenalytics for general life extension
• 10:53
  Speaker 1: yet no, not yet.
• 10:54
  Speaker 2: We are targeting localized pathologies. Dozens of human clinical trials
• 10:58
  Speaker 2: are already underway.
• 10:59
  Speaker 1: Like for pulmonary fibrosis.
• 11:01
  Speaker 2: Right, yes, Idiopathic pulmonary fibrosis is a fatal lung disease
• 11:04
  Speaker 2: driven by progressive scarring. We know sinescent cells drive that
• 11:08
  Speaker 2: fibrotic remodeling.
• 11:09
  Speaker 1: So they are testing if clearing those cells can halt
• 11:13
  Speaker 1: the disease or.
• 11:14
  Speaker 2: Even reverse it. We're seeing similar early stage human trials
• 11:17
  Speaker 2: for ostearthritis targeting the zombie cells in the joint capsule,
• 11:20
  Speaker 2: and even for diabetic kidney disease.
• 11:22
  Speaker 1: That is just why. But you know, while clearing out
• 11:24
  Speaker 1: zombie cells is amazing, it's ultimately essentially taking out the
• 11:27
  Speaker 1: biological track. It's cleanup, yes, but taking out the trash
• 11:30
  Speaker 1: doesn't necessarily improve the function of the cells that are
• 11:33
  Speaker 1: still alive and trying to work. What if we could
• 11:36
  Speaker 1: actually reboot the living cells that have degraded.
• 11:38
  Speaker 2: Now we're moving from cleanup to reprogramming epigenetics.
• 11:42
  Speaker 1: Right. To really grasp this, we have to talk about
• 11:46
  Speaker 1: hardware versus software.
• 11:48
  Speaker 2: It's the best way to visualize it. Every single somatic
• 11:51
  Speaker 2: cell in your body has the exact same genetic sequence.
• 11:55
  Speaker 2: The DNA in your skin cell is identical to the
• 11:59
  Speaker 2: DNA in your heart.
• 12:00
  Speaker 1: The geno is the hardware.
• 12:01
  Speaker 2: Yes, the hardware is identical. What differentiates them is the epigenome,
• 12:05
  Speaker 2: the software.
• 12:06
  Speaker 1: The epigenome decides which genes are turned on or off exactly.
• 12:09
  Speaker 2: It's a complex system of chemical modifications that physically unwind
• 12:13
  Speaker 2: certain sections of DNA so they can be read, and
• 12:15
  Speaker 2: tightly coils other sections to silence them.
• 12:18
  Speaker 1: I've heard you compare it to a symphony before which
• 12:20
  Speaker 1: I love. The genome is the sheet music. It has
• 12:22
  Speaker 1: all the notes, but the epigenome is the conductor, right.
• 12:26
  Speaker 2: The conductor decides which instruments play, how loudly they play,
• 12:30
  Speaker 2: and when they need to stay totally silent.
• 12:32
  Speaker 1: But over time, because of environmental stress, metabolism UV radiation,
• 12:37
  Speaker 1: that conductor starts to lose their place in the sheet music.
• 12:40
  Speaker 2: The epigenetic landscape gets flatten. The software accumulates bugs, so.
• 12:45
  Speaker 1: A heart cell might slightly turn on genes that belong
• 12:47
  Speaker 1: in a liver cell and turn off genes it needs
• 12:50
  Speaker 1: to pump blood precisely.
• 12:51
  Speaker 2: It forgets its original function. It loses its differentiated identity
• 12:55
  Speaker 2: and that epigenetic degradation is a massive driver of aging.
• 12:59
  Speaker 1: So if the issue is buggy software, the solution has
• 13:02
  Speaker 1: to be a factory reset, which brings us to two
• 13:05
  Speaker 1: thousand and six. Shiny Yamanaka's Nobel Prize winning discovery.
• 13:10
  Speaker 2: A truly monumental moment in biology.
• 13:12
  Speaker 1: He figured out that cellular development isn't a one way street.
• 13:15
  Speaker 1: He introduced four specific transcription factors Hockey thirty four, SOCKS two,
• 13:20
  Speaker 1: KLF four, and c.
• 13:22
  Speaker 2: Mic the OSKM factors.
• 13:23
  Speaker 1: Right the Yamanaka factors, and by applying these to an
• 13:26
  Speaker 1: adult cell, he could strip away all the epigenetic marks
• 13:29
  Speaker 1: and reset it all the way back into a youthful
• 13:31
  Speaker 1: embryonic stem cell.
• 13:32
  Speaker 2: Induced pluripotent stem cells. It completely shattered our traditional understanding
• 13:37
  Speaker 2: of biology.
• 13:37
  Speaker 1: The wait I have to bring up a terrifying implication
• 13:39
  Speaker 1: here for the listener. If I press a factory reset
• 13:42
  Speaker 1: button on a heart cell and it becomes an embryonic
• 13:45
  Speaker 1: stem cell, again, doesn't that mean it forgets how to
• 13:48
  Speaker 1: be a heart cell?
• 13:49
  Speaker 2: It completely loses its somatic identity.
• 13:52
  Speaker 1: Yes, so it stops beating. How does that help me
• 13:55
  Speaker 1: live longer? Furthermore, if you inject pluripotent stem cells into
• 14:00
  Speaker 1: an adult body. Don't they just form massive tumors terotomas, Yes.
• 14:04
  Speaker 2: They do. Full reprogramming is entirely lethal to a living organism.
• 14:08
  Speaker 2: You get terotomas everywhere.
• 14:10
  Speaker 1: Okay, So that sounds like a total dead end for antiaging.
• 14:13
  Speaker 2: It was a massive paradox for a while. But the
• 14:15
  Speaker 2: genius breakthrough was bypassing this with a technique called partial
• 14:20
  Speaker 2: epigenetic reprogramming.
• 14:22
  Speaker 1: Partial reprogramming. How does that work?
• 14:24
  Speaker 2: Researchers discovered that reprogramming happens in feeses. The cell erases
• 14:28
  Speaker 2: its biological age, restoring its youthful function before it crosses
• 14:32
  Speaker 2: the threshold of losing its structural identity.
• 14:34
  Speaker 1: Oh wow, So they just pulse the amanoca factors partially exactly.
• 14:38
  Speaker 2: You turn the factors on just long enough to clear
• 14:41
  Speaker 2: the epigenetic noise the bugs in the software, but you
• 14:43
  Speaker 2: flip the switch off before the cell forgets. It's a
• 14:46
  Speaker 2: specialized cell.
• 14:47
  Speaker 1: So the heart cell gets biologically younger, but it keeps
• 14:49
  Speaker 1: beating right.
• 14:50
  Speaker 2: And they often remove the sea mic factor entirely, just
• 14:54
  Speaker 2: using OSK because sea mite is a highly potent oncogene.
• 14:58
  Speaker 2: Removing it makes the whole process that's much safer.
• 15:01
  Speaker 1: Let's talk about a concrete example of this, because the
• 15:04
  Speaker 1: in vivo animal data sounds like absolute science fiction. The
• 15:08
  Speaker 1: optic nerve crush study with the blind.
• 15:10
  Speaker 2: Mice, Oh, that study is a landmark.
• 15:13
  Speaker 1: Usually, the central nervous system in mammals cannot regenerate once
• 15:16
  Speaker 1: it's damaged by age or injury.
• 15:18
  Speaker 2: That's it historically, Yes, But researchers took elderly mice suffering
• 15:22
  Speaker 2: from glaucoma and severe vision loss.
• 15:25
  Speaker 1: Their retinal ganglion cells had accumulated deep epigenetic damage. They
• 15:29
  Speaker 1: were old.
• 15:30
  Speaker 2: So the team introduced those OSK factors directly into the
• 15:34
  Speaker 2: retinas of these old blind mice using a.
• 15:36
  Speaker 1: Viral vector, and they partially pulse the expression right.
• 15:39
  Speaker 2: And the result was mind bending. The OSK factors reversed
• 15:42
  Speaker 2: the epigenetic age of those retinal cells. Once the cells
• 15:45
  Speaker 2: were youthful again, they spontaneously regenerated their connections down the
• 15:49
  Speaker 2: optic nerve.
• 15:49
  Speaker 1: They grew back into the brain.
• 15:51
  Speaker 2: Yes, the old blind mice regained their vision.
• 15:54
  Speaker 1: That is just it's a profound philosophical shift. Cellular age
• 15:58
  Speaker 1: isn't a one way and tropic decay. It is a
• 16:01
  Speaker 1: reversible program.
• 16:03
  Speaker 2: It proves rejuvenation is biologically possible in a living mammal.
• 16:06
  Speaker 1: It's incredible. But you know, while reprogramming this software with
• 16:09
  Speaker 1: viral vectors is amazing, it's also highly complex. Yeah, I
• 16:13
  Speaker 1: want to pivot to something a bit.
• 16:15
  Speaker 2: More innate, the body's own mechanisms.
• 16:17
  Speaker 1: Yeah, before we had genetic engineering, how did evolution design
• 16:21
  Speaker 1: our bodies to maintain themselves in the wild? Because we
• 16:25
  Speaker 1: have a built in starvation switch.
• 16:26
  Speaker 2: Right, we do. And the understand it you have to
• 16:28
  Speaker 2: look at the environment mammalian biology evolved in. It was
• 16:31
  Speaker 2: defined by severe nutritional volatility piast and famine exactly extended
• 16:36
  Speaker 2: periods of caloric abundance followed by prolonged starvation. So evolution
• 16:40
  Speaker 2: built a nutrient sensing network to optimize the body for
• 16:43
  Speaker 2: both extremes.
• 16:44
  Speaker 1: And the central engine of that network is the mTOR
• 16:46
  Speaker 1: pathway mechanistic target of rapamycin.
• 16:49
  Speaker 2: MTR is the master switchboard. It integrates signals, bot amino acids, glucose,
• 16:54
  Speaker 2: cellular energy.
• 16:55
  Speaker 1: So when we eat food, especially protein, mTOR activates.
• 17:00
  Speaker 2: Right, MTR complex one activates and it tells the cell
• 17:03
  Speaker 2: to grow, build new proteins, divide. It's a massive anabolic cascade,
• 17:08
  Speaker 2: which is great.
• 17:09
  Speaker 1: If you are growing or recovering from an injury.
• 17:11
  Speaker 2: But chronic activation is dangerous because when MTR is turned on,
• 17:15
  Speaker 2: it actively shuts down the body's repair mechanisms. Specifically, it
• 17:20
  Speaker 2: inhibits autophogy.
• 17:21
  Speaker 1: Autophogy the self eating process.
• 17:23
  Speaker 2: Yes, when food is scarce and MTR shuts down, autophagy begins.
• 17:28
  Speaker 2: The cell forms a membrane that swallows up damaged organelles,
• 17:31
  Speaker 2: misfolded proteins, cellular junk. Recycles the garbage exactly, it breaks
• 17:36
  Speaker 2: it all down into basic amino acids for survival, and
• 17:39
  Speaker 2: in doing so, it clears out the exact types of
• 17:41
  Speaker 2: intracellular damage that drive aging.
• 17:43
  Speaker 1: So starvation triggers the ultimate deed clean But this brings
• 17:46
  Speaker 1: up the modern problem for everyone listening. Our environment right,
• 17:50
  Speaker 1: we live in an era of constant hyperchloric abundance. We
• 17:53
  Speaker 1: eat high protein, high sugar meals from the moment we
• 17:55
  Speaker 1: wake up until we go to bed.
• 17:56
  Speaker 2: We are never in a prolonged fasted state.
• 17:59
  Speaker 1: So om MR pathways is constantly activated. We are permanently
• 18:02
  Speaker 1: stuck in growth mode.
• 18:04
  Speaker 2: Which means our cellular cleanup mechanisms are permanently shut down.
• 18:08
  Speaker 2: The intracellular debris just accumulates, driving neurodegeneration and systemic dysfunction.
• 18:13
  Speaker 1: So the obvious answer is we should all just fast
• 18:15
  Speaker 1: for long periods. But practically, chronic caloric restriction is miserable.
• 18:21
  Speaker 1: Humans hate it.
• 18:22
  Speaker 2: The compliance rates are terribly.
• 18:24
  Speaker 1: Low, which is why the pharmacological biohack is so exciting.
• 18:27
  Speaker 1: We have a molecule that fools the body into thinking
• 18:29
  Speaker 1: it's starving even when it's not.
• 18:31
  Speaker 2: Rapamycin.
• 18:32
  Speaker 1: Rapamycin found in the soil of Easter Island of all places.
• 18:36
  Speaker 2: Yes, produced by a soil bacterium. Rapamcin directly binds to
• 18:40
  Speaker 2: and inhibits mTOR.
• 18:41
  Speaker 1: So you take this drug, it suppresses mTOR and it
• 18:44
  Speaker 1: supercharges atophagy and cellul repair. You give the benefits of
• 18:47
  Speaker 1: starvation without actually starving.
• 18:49
  Speaker 2: And it is currently the most reliable pharmacological life span
• 18:52
  Speaker 2: extender we have in mammalian testing. It consistently lengthens mouse
• 18:56
  Speaker 2: lifespans by ten percent to twenty five percent, and given
• 19:00
  Speaker 2: late in life, it delays the onset of almost every
• 19:03
  Speaker 2: age related pathology and mice.
• 19:05
  Speaker 1: Okay, but I have to push you on the reality
• 19:07
  Speaker 1: check here, because extending a mouse's life in a sterile
• 19:10
  Speaker 1: lab is very different from giving this to a human
• 19:14
  Speaker 1: walking around in the real world.
• 19:15
  Speaker 2: Oh absolutely.
• 19:16
  Speaker 1: Wrapamycin is literally FDA approved right now as an immunosuppressant.
• 19:21
  Speaker 1: It's given to organ transplant patients so their bodies don't
• 19:24
  Speaker 1: reject the new organ right.
• 19:25
  Speaker 2: Because MTR is crucial for the proliferation of immune cells
• 19:29
  Speaker 2: like T cells.
• 19:30
  Speaker 1: So if you chronically suppress mTOR to live longer, you
• 19:33
  Speaker 1: are simultaneously crashing your immune system. That leaves the listener
• 19:38
  Speaker 1: incredibly vulnerable to just you know, everyday infections, And that.
• 19:43
  Speaker 2: Is the massive trade off. If you decelerate cellular aging
• 19:46
  Speaker 2: but die of a standard respiratory infection because your immune
• 19:49
  Speaker 2: system is suppressed, you haven't wont anything.
• 19:51
  Speaker 1: So how do we safely translate this to humans.
• 19:54
  Speaker 2: The current frontier is intermittent dosing, finding the precise chronopharmacology.
• 19:59
  Speaker 1: Pulsing it basically, but instead.
• 20:00
  Speaker 2: Of a daily dose, researchers are looking at weekly or
• 20:03
  Speaker 2: bi weekly pulses. You trigger autophagy to clear the debris,
• 20:07
  Speaker 2: then let mTOR reactivate so the immune system can function.
• 20:11
  Speaker 1: Have there been human trials on that kind of pulsing.
• 20:13
  Speaker 2: There have studies using similar mTOR inhibitors, and elderly populations
• 20:19
  Speaker 2: showed that intermittent dosing actually upregulated their immune response, reducing
• 20:24
  Speaker 2: respiratory infections.
• 20:25
  Speaker 1: Wait, really it improved their immune system.
• 20:28
  Speaker 2: Yes, because it cleared out the exhausted immune cells and
• 20:30
  Speaker 2: allowed fresh ones to function better. It's all about the timing.
• 20:34
  Speaker 1: That is fascinating. Okay, So we have zombie killing se analytics,
• 20:38
  Speaker 1: we have cellular software reboots with OSK, and we have
• 20:42
  Speaker 1: starvation pills like rapamycin that work beautifully in mice.
• 20:45
  Speaker 2: Biology is sound.
• 20:47
  Speaker 1: So I have to speak for the listener's inevitable frustration
• 20:49
  Speaker 1: right now. If we have all these miracles, why aren't
• 20:52
  Speaker 1: these anti aging therapies available at my local pharmacy today?
• 20:56
  Speaker 2: Because the biological and structural roadblocks are monumental.
• 21:00
  Speaker 1: Let's talk about them. Roadblock number one regulatory bottlenecks the FDA.
• 21:06
  Speaker 2: The entire FDA framework is built on a disease specific model.
• 21:10
  Speaker 2: A drug must be proven to treat a specific recognized.
• 21:13
  Speaker 1: Disease like diabetes or cancer exactly.
• 21:16
  Speaker 2: But the FDA does not recognize aging as a disease.
• 21:19
  Speaker 2: It's considered a natural biological process.
• 21:22
  Speaker 1: So you literally cannot run a clinical trial for an
• 21:24
  Speaker 1: anti aging drug.
• 21:26
  Speaker 2: Legally, no, you can't have aging as your primary indication.
• 21:29
  Speaker 1: Which means buyer tech companies have to creatively reframe their
• 21:32
  Speaker 1: longevity drugs as treatments for very narrow specific diseases.
• 21:37
  Speaker 2: It's a huge bureaucratic dance. A prime example of trying
• 21:40
  Speaker 2: to break this is the Tame trial targeting aging with
• 21:44
  Speaker 2: met Foreman.
• 21:44
  Speaker 1: Ah. Yeah, the tain trial. How are they getting around
• 21:47
  Speaker 1: the FDA rules?
• 21:48
  Speaker 2: They are using a composite endpoint. They aren't saying that
• 21:50
  Speaker 2: Foreman cures aging. They are tracking elderly patients to see
• 21:54
  Speaker 2: if it delays the onset of a cluster of diseases
• 21:57
  Speaker 2: cardiovascular events, cancer, cognitive decline, all at once.
• 22:00
  Speaker 1: So if they prove it delays all those, the FDA
• 22:03
  Speaker 1: might finally validate a drug for general age related multi
• 22:06
  Speaker 1: morbidity exactly.
• 22:08
  Speaker 2: It would establish a regulatory pathway for true longevity drugs.
• 22:11
  Speaker 1: But even if the FDA changes the rules, there is
• 22:14
  Speaker 1: a logistical nightmare here. Trial time spans.
• 22:18
  Speaker 2: Human beings live a very long.
• 22:20
  Speaker 1: Time, right. If you want to prove a drug extends
• 22:23
  Speaker 1: maximum human life span, you'd have to run a trial
• 22:25
  Speaker 1: for what eighty years at.
• 22:27
  Speaker 2: Least, and that is economically and structurally unfeasible. The original
• 22:31
  Speaker 2: researchers would be long dead.
• 22:33
  Speaker 1: So how do you prove a drug make someone biologically
• 22:36
  Speaker 1: younger in just a few years.
• 22:37
  Speaker 2: You have to rely on surrogate biomarkers, specifically epigenetic clocks
• 22:42
  Speaker 2: like the DNA methylation clocks developed by Steve Horvath.
• 22:46
  Speaker 1: Oh right, we talked about the software earlier. So these
• 22:49
  Speaker 1: clocks measure the exact biological age of your DNA software.
• 22:53
  Speaker 2: Yes, by analyzing the methylation patterns in a simple blood draw,
• 22:57
  Speaker 2: they can predict your biological age and morte risk with
• 23:00
  Speaker 2: incredible accuracy.
• 23:02
  Speaker 1: So in a trial, you give the patient the drug
• 23:05
  Speaker 1: and a year later you check their blood to see
• 23:07
  Speaker 1: if the epigenetic clock reversed.
• 23:09
  Speaker 2: That's the goal. The problem is the regulatory bodies are
• 23:12
  Speaker 2: agonizingly slow to validate these new metrics as official end
• 23:15
  Speaker 2: points for drug approval.
• 23:17
  Speaker 1: So until the FDA accepts the clocks, the commercial pipeline
• 23:20
  Speaker 1: is totally.
• 23:21
  Speaker 2: Bottle neck, completely bottleneck.
• 23:22
  Speaker 1: And then there is roadblock three, and this is deeply biological.
• 23:26
  Speaker 1: The cancer rejuvenation trade off.
• 23:28
  Speaker 2: The most terrifying hurdle of all.
• 23:30
  Speaker 1: I like to use a car analogy for this, If
• 23:32
  Speaker 1: you push the gas pedal on cellular rejuvenation, are you
• 23:36
  Speaker 1: accidentally cutting the brakes?
• 23:37
  Speaker 2: That is exactly what you were doing. The biological overlap
• 23:40
  Speaker 2: between a rejuvenated cell and a malignant cancerous cell is
• 23:44
  Speaker 2: uncomfortably large. Also, think about what a cancer cell does.
• 23:48
  Speaker 2: It bypasses senescence, it maintains its telomeres so it can
• 23:53
  Speaker 2: divide infinitely, and it undergoes de differentiation. It becomes highly
• 23:57
  Speaker 2: plastic and stem like.
• 23:58
  Speaker 1: Wait, that sounds exactly like what we are trying to
• 24:00
  Speaker 1: do with cellular reprogramming.
• 24:02
  Speaker 2: It is when we use epigenetic reprogramming or extend telomeres,
• 24:06
  Speaker 2: we are intentionally inducing cellular plasticity and promoting rapid cell growth.
• 24:11
  Speaker 1: We are pushing the exact same pathways that tumors use.
• 24:14
  Speaker 2: Yes, the therapeutic window is microscopically thin, prompting cells to
• 24:18
  Speaker 2: divide rapidly or regain stem like properties, risks triggering uncontrolled
• 24:23
  Speaker 2: cell growth.
• 24:24
  Speaker 1: So if you aren't perfectly precise, your anti aging therapy
• 24:27
  Speaker 1: just gives the patient aggressive cancer.
• 24:29
  Speaker 2: Exactly, which is why the safety profiling for these drugs
• 24:32
  Speaker 2: takes decades.
• 24:33
  Speaker 1: Wow. Okay, so keeping all these biological and bureaucratic hurdles
• 24:36
  Speaker 1: in mind. Let's ground this in reality for the listener.
• 24:40
  Speaker 1: Are we going to become immortal by twenty fifty?
• 24:42
  Speaker 2: It is highly, highly unlikely we will achieve true immortality
• 24:46
  Speaker 2: anytime soon.
• 24:47
  Speaker 1: Let's reframe the goal then.
• 24:49
  Speaker 2: The actual goal of longevity science is adding health to
• 24:53
  Speaker 2: our years, not just years to our lives. The compression
• 24:56
  Speaker 2: of morbidity.
• 24:57
  Speaker 1: Right, instead of being sick for the last twenty years
• 24:58
  Speaker 1: of your life, you stay healthy and fully functional until
• 25:01
  Speaker 1: right at the very.
• 25:02
  Speaker 2: End, exactly squaring the survival curve.
• 25:04
  Speaker 1: So what's the realistic timeline. Let's look at the low
• 25:06
  Speaker 1: hanging fruit the next five to ten years. What's actually
• 25:09
  Speaker 1: hitting the market.
• 25:10
  Speaker 2: In the next five to ten years, we will likely
• 25:12
  Speaker 2: see target specific scenolytics and mTOR modulators hit the clinic.
• 25:17
  Speaker 1: But not as a general anti aging pill.
• 25:19
  Speaker 2: No, they will be approved for specific age related conditions,
• 25:24
  Speaker 2: like an injection into the knee to clear sinescent cells
• 25:26
  Speaker 2: for osteoarthritis, or localized m TR treatments for macular degeneration, very.
• 25:31
  Speaker 1: Targeted symptom management using longevity tools. What about ten to
• 25:35
  Speaker 1: twenty years from now, the midterm.
• 25:37
  Speaker 2: Horizon, that's when we expect to see phase three human
• 25:40
  Speaker 2: testing for general systemic health span.
• 25:42
  Speaker 1: Extensions, systemic interventions like what.
• 25:45
  Speaker 2: Validated gene therapies, advanced NAD plus boosters to restore mitochondrial
• 25:50
  Speaker 2: functions systemically, and the first clinical applications of those partial
• 25:54
  Speaker 2: epigenetic reprogramming cocktails. We discussed the.
• 25:58
  Speaker 1: OSK factors, but carefully controlled.
• 26:00
  Speaker 2: Yes, targeting high risk cohorts first.
• 26:03
  Speaker 1: And what about thirty plus years the long term future.
• 26:06
  Speaker 1: This is where it starts sounding like sci fi.
• 26:07
  Speaker 2: Right, it does sound like science fiction, but it's biologically
• 26:10
  Speaker 2: feasible thirty years out. We are looking at advanced stem
• 26:14
  Speaker 2: cell replacements, whole organ bioprinting using your own reprogrammed cells
• 26:19
  Speaker 2: so you.
• 26:19
  Speaker 1: Just print a new liver if yours.
• 26:20
  Speaker 2: Fails exactly, and potentially systemic genomic reprogramming.
• 26:25
  Speaker 1: Systemic so you could actually have someone living past one
• 26:28
  Speaker 1: hundred with the biological body and molecular gamage profile of
• 26:31
  Speaker 1: a forty year old.
• 26:32
  Speaker 2: That is the theoretical endpoint of the field.
• 26:34
  Speaker 1: Yes, that is just stunning, but it brings us to
• 26:37
  Speaker 1: a really stark reality for the present. If the truly
• 26:41
  Speaker 1: radical systemic interventions are ten to thirty years away, what
• 26:45
  Speaker 1: is the strategy for the person listening to us right now.
• 26:48
  Speaker 2: The immediate objective is very simple, live long enough to
• 26:51
  Speaker 2: benefit from the medicine arriving.
• 26:53
  Speaker 1: Tomorrow, the bridge to tomorrow.
• 26:55
  Speaker 2: Yes, you have to maintain your structural integrity now so
• 26:59
  Speaker 2: you are healthy enough to actually receive the advanced therapeutics
• 27:02
  Speaker 2: when they cleill the FDA.
• 27:04
  Speaker 1: And the irony here is that the current arsenal the
• 27:07
  Speaker 1: most effective longevity tools we control right now. They aren't
• 27:10
  Speaker 1: high tech at.
• 27:11
  Speaker 2: All, are they No, they don't require viral vectors or prescriptions.
• 27:14
  Speaker 2: The most powerful epigenetic modifiers we have are behavioral.
• 27:18
  Speaker 1: Like exercise, yeah, optimizing sleep, gut health. But I want
• 27:22
  Speaker 1: to be clear, we aren't just giving generic eat your
• 27:24
  Speaker 1: veggies advice here. These behaviors target the exact same molecular
• 27:28
  Speaker 1: pathways we've been talking about precisely.
• 27:30
  Speaker 2: Let's look at rigorous aerobic and resistance training. When you
• 27:34
  Speaker 2: lift heavy things, you activate an energy sensor called AMPK,
• 27:38
  Speaker 2: which does what When AMPK is activated by exercise, it
• 27:41
  Speaker 2: directly inhibits the mtoor pathway.
• 27:44
  Speaker 1: Oh so it acts just like rapamycin. It chemically forces
• 27:47
  Speaker 1: the cells into that state of autopogy and repair exactly.
• 27:51
  Speaker 2: It forces the clearance of sinescent cellular debris. Exercise also
• 27:55
  Speaker 2: stimulates PGC one alpha, which reverses mitochondrial dysfunction.
• 28:00
  Speaker 1: Working out is literally hacking the MTIO pathway. What about sleep?
• 28:03
  Speaker 1: Why is sleep so critical for longevity?
• 28:05
  Speaker 2: Because of the glymphatic system in the brain. During deep
• 28:09
  Speaker 2: slow wave sleep, the space between your neurons actually physically expands.
• 28:13
  Speaker 1: Oh really, yes, it.
• 28:14
  Speaker 2: Allows cerebras spinal fluid to wash through the brain tissue,
• 28:17
  Speaker 2: flushing out all the toxic metabolic byproducts from the day,
• 28:20
  Speaker 2: like amyloid beta.
• 28:22
  Speaker 1: The protein that drives Alzheimer's.
• 28:23
  Speaker 2: Exactly, chronic sleep deprivation directly accelerates the accumulation of those proteins.
• 28:28
  Speaker 2: It drives epigenetic degradation.
• 28:30
  Speaker 1: So it's a poetic irony to unlock the sci fi
• 28:33
  Speaker 1: future of epigenetic reprogramming and senoltic zombie killers. The absolute
• 28:37
  Speaker 1: best thing you can do today is lift heavy things,
• 28:40
  Speaker 1: go for a run, and get eight hours of sleep.
• 28:42
  Speaker 2: You cannot outprescribe a sedentary lifestyle. The advanced therapies of
• 28:47
  Speaker 2: tomorrow won't work on a body that has been utterly
• 28:50
  Speaker 2: degraded by decades of metabolic neglect.
• 28:53
  Speaker 1: Right, your daily habits are actively modulating your epigenome.
• 28:57
  Speaker 2: Right now, every dietary choice, every workout alters the expression
• 29:01
  Speaker 2: of your DNA.
• 29:02
  Speaker 1: Well, we have covered an immense expanse of biology today.
• 29:06
  Speaker 1: We started by deconstructing that historical fatalism, the idea that
• 29:09
  Speaker 1: aging is just a mystical, inevitable decay, and replaced it
• 29:13
  Speaker 1: with a mechanical framework of twelve solvable hallmarks.
• 29:16
  Speaker 2: A very mechanical, actionable framework.
• 29:19
  Speaker 1: We looked at deploying scenalytics to clear out those toxic
• 29:22
  Speaker 1: ssas P secreting zombie cells. We talked about using Yamanaka
• 29:26
  Speaker 1: factors to literally reboot the cellular software, reversing the epigenetic claws,
• 29:30
  Speaker 1: and pharmacologically hacking the mTOR pathway with rapamycin to trigger
• 29:35
  Speaker 1: the bodies innate starvation repair systems.
• 29:37
  Speaker 2: All balanced against some very severe clinical realities of course,
• 29:40
  Speaker 2: right the.
• 29:41
  Speaker 1: Rigid FDA disease frameworks, the need for validated methylation clocks,
• 29:45
  Speaker 1: and that terrifying biological tightrope between cellular rejuvenation and cancer.
• 29:49
  Speaker 2: It is a complex landscape, but incredibly promising and.
• 29:53
  Speaker 1: Ultimately the path forward for you, the listener relies on
• 29:58
  Speaker 1: leveraging your innate physiog today to build that bridge to
• 30:02
  Speaker 1: the therapeutics of tomorrow. It is an incredible shift in
• 30:05
  Speaker 1: medical science.
• 30:06
  Speaker 2: It really is. But as we look toward this future,
• 30:09
  Speaker 2: there is a broader implication that I think requires careful consideration.
• 30:13
  Speaker 1: Oh what's that?
• 30:14
  Speaker 2: Well, we focus so intensely on the molecular mechanisms of
• 30:18
  Speaker 2: extending health span, right, but we rarely examine the sociological impact.
• 30:23
  Speaker 1: That's a great point.
• 30:24
  Speaker 2: Think about it. If these breakthrough succeed and the traditional
• 30:27
  Speaker 2: retirement age of sixty five becomes merely the midpoint of
• 30:30
  Speaker 2: a healthy adult life, how will society entirely restructure itself?
• 30:34
  Speaker 1: Everything would change exactly.
• 30:35
  Speaker 2: What happens to human ambition, to our relationships, to our
• 30:38
  Speaker 2: very psyche when the ticking biological clock that has defined
• 30:42
  Speaker 2: the human experience for millennia is fundamentally slowed down.
• 30:45
  Speaker 1: Wow, that is a profound question to leave on a
• 30:48
  Speaker 1: structurally different human experience. Well, thank you all for joining
• 30:51
  Speaker 1: us on this deep dive into the future of longevity.